Effects of bradykinin on coronary blood flow and vasomotion in transplant patients

E Aptecar1, E Teiger, P Dupouy

  • 1Fédération de Cardiologie et Institut National de la Santé et de la Recherche Médicale U400, Créteil, France. eaptecar@club-inernet.fr

Insights

Bradykinin preserves coronary vasodilation in heart transplant patients, even with rejection. Acetylcholine causes abnormal vasoconstriction, indicating preserved endothelial function post-transplant.

Area of Science:

  • Cardiology
  • Transplant Medicine
  • Vascular Biology

Background:

  • Coronary endothelial dysfunction is common early after heart transplantation.
  • Acetylcholine has been used to identify this dysfunction.
  • Bradykinin's effects on coronary vasomotion in transplant patients are unknown.

Purpose of the Study:

  • To assess exogenous bradykinin's impact on coronary epicardial and microcirculatory tone in heart transplant recipients (HTXs).
  • To compare bradykinin's effects with those of acetylcholine in HTXs.

Main Methods:

  • Compared 16 HTXs (3.6 months post-transplant) with 7 controls.
  • Measured coronary flow velocity using guide-wire Doppler.
  • Assessed left coronary artery diameter and coronary blood flow (CBF) during bradykinin and acetylcholine infusions.

Main Results:

  • Bradykinin caused dose-dependent vasodilation and increased CBF in both HTXs and controls.
  • Acetylcholine induced vasodilation in controls but vasoconstriction in HTXs.
  • Acute allograft rejection did not alter bradykinin response but reduced acetylcholine-induced CBF increase.

Conclusions:

  • Coronary vasodilating effects of bradykinin are maintained early after heart transplantation.
  • Despite abnormal acetylcholine response suggesting endothelial dysfunction, the endothelium remains functionally active in HTXs.
  • Bradykinin serves as a reliable vasodilator in heart transplant recipients.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...